Mobic is the brand name for meloxicam, a nonsteroidal anti-inflammatory drug, or NSAID, that is used to treat pain associated with osteoarthritis, rheumatoid arthritis and juvenile rheumatoid arthritis. This drug belongs to a category known as COX-2 selective inhibitors; that is, it inhibits the production of substances known as prostaglandins, which are involved in pain and inflammatory responses. Mobic usually is well-tolerated, however, individuals with cardiovascular disease or gastrointestinal disease are at greater risk for serious adverse effects, including heart attacks or gastrointestinal bleeding. Otherwise, mild side effects typically are related to this medication.
Indigestion
All NSAID drugs may produce gastrointestinal side effects at the start of new drug therapy, and Mobic is no exception. During clinical trials, according to eMedTv.com, the most frequently reported side effect was indigestion or heartburn, which occurred in up to 9.5 percent of the participants who were in the experimental group. This adverse reaction may be accompanied by an upset stomach and excess gas. Such commonly observed effects are considered to be mild and temporary; that is, they tend to resolve on their own as the body adjusts to the new medication. Notify the prescribing physician if these symptoms persist or become worrisome.
Infections
Contracting common infections is another frequent side effect that is associated with Mobic therapy. Specifically, RxList.com states that during the clinical trials, up to 8.3 percent of the participants on this medication came down with upper respiratory infections, including flu-like viruses. Another infection that may occur in some patients is a urinary tract infection; up to 6.9 percent of the participants on this drug during clinical trials acquired urinary tract infections. Contact the prescribing physician if infectious-like symptoms present so that they can be evaluated and treated.
Diarrhea and Nausea
According to the Boehringer-Ingelheim website and eMedTv.com, another frequent adverse reaction to this NSAID medication is diarrhea, which occurred in up to 7.8 percent of the participants during clinical trials. This symptom may be accompanied by abdominal pain. Additionally, up to 7.2 percent of participants on Mobic during the trials complained of nausea. If the nausea or diarrhea does not subside, contact the prescribing physician promptly so that you do not become dehydrated from the loss of fluids.
Pain and Edema
At the beginning of Mobic therapy, some individuals may experience various types of pain. For example, according to the Boehringer-Ingelheim website, up to 8.3 percent of clinical trial participants reported having headaches, while joint pain occurred in up to 5.3 percent of those in the experimental group. Also, edema, or the retention of fluid, may present in such areas of the body as the lower extremities. You should monitor these pain and swelling symptoms, and promptly contact the doctor if they persist or increase in severity.
Member Comments